Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.

Saved in:
Bibliographic Details
Title: Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.
Authors: Copeland NK; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Otieno L; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Otieno JD; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Otieno S; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Chira S; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Ivinson K; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Onyango I; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Wasuna R; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Akala H; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Onditi A; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Sifuna P; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Andagalu B; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Oyugi R; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Omondi M; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Amoit S; Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya., Locke E; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Gregory S; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Bergmann-Leitner ES; Biologics Research & Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA., Pindolia H; Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom., Raine M; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Gast C; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Mercer LD; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Aponte JJ; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Lievens M; Vaccine Clinical R&D, GlaxoSmithKline, Wavre, Belgium., Ockenhouse CF; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland., Lee CK; Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland.
Source: The Journal of infectious diseases [J Infect Dis] 2025 Sep 15; Vol. 232 (3), pp. e372-e382.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1537-6613
DOI:10.1093/infdis/jiaf274